ANEB
NASDAQ · Pharmaceuticals
Anebulo Pharmaceuticals Inc
$1.03
+0.01 (+0.98%)
Financial Highlights (FY 2025)
Revenue
5.41M
Net Income
1.02M
Gross Margin
60.3%
Profit Margin
18.8%
Rev Growth
+9.4%
D/E Ratio
0.83
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 60.3% | 60.3% | 60.3% |
| Operating Margin | 22.3% | 18.9% | 20.4% |
| Profit Margin | 18.8% | 14.9% | 14.0% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.41M | 5.09M | 4.82M |
| Gross Profit | 3.26M | 3.07M | 2.91M |
| Operating Income | 1.21M | 962.6K | 982.7K |
| Net Income | 1.02M | 757.9K | 675.0K |
| Gross Margin | 60.3% | 60.3% | 60.3% |
| Operating Margin | 22.3% | 18.9% | 20.4% |
| Profit Margin | 18.8% | 14.9% | 14.0% |
| Rev Growth | +9.4% | +17.9% | +10.5% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 9.81M | 10.33M | 7.88M |
| Total Equity | 11.87M | 12.73M | 13.19M |
| D/E Ratio | 0.83 | 0.81 | 0.60 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 1.84M | 1.51M | 1.49M |
| Free Cash Flow | 747.3K | 835.9K | 744.4K |